Bridge Biotherapeutics terminates collaboration agreement with Boehringer

Under the latest deal, Bridge Biotherapeutics will regain all rights to BBT-877. Credit: © Boehringer Ingelheim.



  • Bridge Biotherapeutics; Boehringer Ingelheim